Corvus Pharmaceuticals, Inc. Operating Lease Cost
Corvus Pharmaceuticals, Inc. (CRVS) reported Operating Lease Cost of $1.22 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2024-03-19
- Corvus Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2023-03-31 was $306.00K, a 0.00% change year-over-year.
- Corvus Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2022-12-31 was $305.00K, a 0.33% decline year-over-year.
- Corvus Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2022-09-30 was $306.00K, a 17.24% increase year-over-year.
- Corvus Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2022-06-30 was $134.00K, a 43.93% decline year-over-year.
- Corvus Pharmaceuticals, Inc. operating lease, cost for fiscal 2023 was $1.22M, a 16.46% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. operating lease, cost for fiscal 2022 was $1.05M, a 0.48% increase from fiscal 2021.
- Corvus Pharmaceuticals, Inc. operating lease, cost for fiscal 2021 was $1.05M, a 9.30% increase from fiscal 2020.
- Corvus Pharmaceuticals, Inc. operating lease, cost for fiscal 2020 was $957.00K, a 0.31% decline from fiscal 2019.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.22M 10-K · filed 2024-03-19 | |||
| 2023-03-31 | $306.00K 10-Q · filed 2023-05-08 | $611.00K derived: sum of 2 quarters · filed 2024-03-19 | $917.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.05M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $611.00K derived: sum of 2 quarters · filed 2024-03-19 | $745.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.05M 10-K · filed 2024-03-19 |
| 2022-09-30 | $306.00K 10-Q · filed 2022-11-03 | $440.00K derived: sum of 2 quarters · filed 2022-11-03 | $746.00K 10-Q · filed 2022-11-03 | $1.05M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $134.00K 10-Q · filed 2022-08-08 | $440.00K 10-Q · filed 2022-08-08 | $746.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.01M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $306.00K 10-Q · filed 2023-05-08 | $612.00K derived: sum of 2 quarters · filed 2024-03-19 | $873.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.11M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $306.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $567.00K derived: sum of 2 quarters · filed 2024-03-19 | $806.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.05M 10-K · filed 2024-03-19 |
| 2021-09-30 | $261.00K 10-Q · filed 2022-11-03 | $500.00K derived: sum of 2 quarters · filed 2022-11-03 | $740.00K 10-Q · filed 2022-11-03 | $978.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $239.00K 10-Q · filed 2022-08-08 | $478.00K 10-Q · filed 2022-08-08 | $717.00K derived: sum of 3 quarters · filed 2023-03-28 | $956.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $239.00K 10-Q · filed 2022-05-05 | $478.00K derived: sum of 2 quarters · filed 2023-03-28 | $717.00K derived: sum of 3 quarters · filed 2023-03-28 | $956.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $239.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $478.00K derived: sum of 2 quarters · filed 2023-03-28 | $717.00K derived: sum of 3 quarters · filed 2023-03-28 | $957.00K 10-K · filed 2023-03-28 |
| 2020-09-30 | $239.00K 10-Q · filed 2021-11-01 | $478.00K derived: sum of 2 quarters · filed 2021-11-01 | $718.00K 10-Q · filed 2021-11-01 | $957.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $239.00K 10-Q · filed 2021-08-02 | $478.00K 10-Q · filed 2021-08-02 | $718.00K derived: sum of 3 quarters · filed 2022-03-10 | $957.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $239.00K 10-Q · filed 2021-04-29 | $479.00K derived: sum of 2 quarters · filed 2022-03-10 | $718.00K derived: sum of 3 quarters · filed 2022-03-10 | $951.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $479.00K derived: sum of 2 quarters · filed 2022-03-10 | $712.00K derived: sum of 3 quarters · filed 2022-03-10 | $960.00K 10-K · filed 2022-03-10 |
| 2019-09-30 | $239.00K 10-Q · filed 2020-10-29 | $472.00K derived: sum of 2 quarters · filed 2020-10-29 | $720.00K 10-Q · filed 2020-10-29 | $958.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $233.00K 10-Q · filed 2020-07-30 | $481.00K 10-Q · filed 2020-07-30 | $719.00K derived: sum of 3 quarters · filed 2021-03-25 | $885.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $249.00K 10-Q · filed 2020-04-30 | $486.00K derived: sum of 2 quarters · filed 2021-03-25 | $652.00K derived: sum of 3 quarters · filed 2021-03-25 | $819.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $403.00K derived: sum of 2 quarters · filed 2021-03-25 | $570.00K derived: sum of 3 quarters · filed 2021-03-25 | $748.00K 10-K · filed 2021-03-25 |
| 2018-09-30 | $166.00K 10-Q · filed 2019-10-29 | $333.00K derived: sum of 2 quarters · filed 2019-10-29 | $511.00K 10-Q · filed 2019-10-29 | |
| 2018-06-30 | $167.00K 10-Q · filed 2019-08-01 | $344.00K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $177.00K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $734.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |